

Title (en)  
CHIMERIC ANTIGEN RECEPTORS WITH ENHANCED NFkB SIGNALING

Title (de)  
CHIMÄRE ANTIGENREZEPTOREN MIT VERBESSERTER NFkB-SIGNALGEBUNG

Title (fr)  
RÉCEPTEURS ANTIGÉNIQUES CHIMÉRIQUES À SIGNALISATION DE NFkB AMÉLIORÉE

Publication  
**EP 3684424 A4 20210929 (EN)**

Application  
**EP 18859613 A 20180911**

Priority

- US 201762561815 P 20170922
- US 201762597128 P 20171211
- US 201862640153 P 20180308
- US 201862666381 P 20180503
- US 201862666385 P 20180503
- US 2018050417 W 20180911

Abstract (en)  
[origin: WO2019060174A1] Disclosed herein are chimeric antigen receptor (CAR) polypeptides, which can be used with adoptive cell transfer to target and kill cancers, that comprise a co-stimulatory signaling region having a mutated form of a cytoplasmic domain of CD28 that enhances CAR-T cell function, a mutated form of a cytoplasmic domain of 41BB that enhances nuclear factor kappaB (NFkB) signaling, or a combination thereof. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Also disclosed are immune effector cells co-expressing a CAR and one or more TRAF proteins. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a tumor associated antigen-expressing cancer that involves adoptive transfer of the disclosed immune effector cells.

IPC 8 full level  
**A61K 48/00** (2006.01); **A61K 39/00** (2006.01); **A61P 35/00** (2006.01); **C07H 21/04** (2006.01); **C07K 14/705** (2006.01); **C07K 14/725** (2006.01); **C07K 16/00** (2006.01); **C07K 16/28** (2006.01); **C12N 5/071** (2010.01); **C12N 5/0783** (2010.01); **C12N 5/16** (2006.01); **C12N 15/00** (2006.01)

CPC (source: EP US)  
**A61K 39/4611** (2023.05 - EP US); **A61K 39/4631** (2023.05 - EP US); **A61K 39/464412** (2023.05 - EP US); **A61K 2239/31** (2023.05 - US); **A61K 2239/38** (2023.05 - US); **A61K 2239/48** (2023.05 - US); **A61P 35/00** (2018.01 - EP); **C07K 14/7051** (2013.01 - EP); **C07K 14/70521** (2013.01 - EP US); **C07K 16/2803** (2013.01 - EP US); **C12N 5/0638** (2013.01 - EP US); **A61K 48/00** (2013.01 - EP); **A61K 2039/505** (2013.01 - EP); **A61K 2239/31** (2023.05 - EP); **A61K 2239/38** (2023.05 - EP); **A61K 2239/48** (2023.05 - EP); **C07K 2317/622** (2013.01 - EP US); **C07K 2319/02** (2013.01 - EP US); **C07K 2319/03** (2013.01 - EP US); **C07K 2319/33** (2013.01 - EP US); **C07K 2319/70** (2013.01 - EP US); **C12N 2501/515** (2013.01 - EP US); **C12N 2510/00** (2013.01 - EP US); **C12N 2740/13043** (2013.01 - EP)

Citation (search report)

- [X] US 2014328812 A1 20141106 - CAMPANA DARIO [SG], et al
- [A] WO 2014127261 A1 20140821 - UNIV CALIFORNIA [US]
- [X] LI GONGBO ET AL: "Mutation of the 41BB co-stimulatory domain enhances CAR signaling and mouse CD19-targeted CAR T cell function", 1 February 2017 (2017-02-01), XP009527374, Retrieved from the Internet <URL:https://www.researchgate.net/publication/314151105\_Mutation\_of\_the\_41BB\_co-stimulatory\_domain\_enhances\_CAR\_signaling\_and\_mouse\_CD19-targeted\_CAR\_T\_cell\_function> [retrieved on 20210506], DOI: 10.13140/RG.2.2.14247.75682
- [X] LI GONGBO ET AL: "Optimization of Murine 4-1BB Signaling Results in Enhanced CD19-Targeted CAR T Cell Function in Immune Competent Mice", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 23, no. 3, 1 March 2017 (2017-03-01), XP029931874, ISSN: 1083-8791, DOI: 10.1016/J.BBMT.2016.12.417
- [X] ADRIENNE H LONG ET AL: "4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors", NATURE MEDICINE, vol. 21, no. 6, 4 May 2015 (2015-05-04), New York, pages 581 - 590, XP055278553, ISSN: 1078-8956, DOI: 10.1038/nm.3838
- [XP] DIOGO GOMES-SILVA ET AL: "Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent", CELL REPORTS, vol. 21, no. 1, 1 October 2017 (2017-10-01), US, pages 17 - 26, XP055690717, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2017.09.015
- [I] M. SADELAIN ET AL: "The Basic Principles of Chimeric Antigen Receptor Design", CANCER DISCOVERY, vol. 3, no. 4, 1 April 2013 (2013-04-01), US, pages 388 - 398, XP055287277, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-12-0548
- [A] POSEY AVERY D ET AL: "Mixed Signals: Alteration of CD28 Signaling Motifs Improves Anti-Tumor Efficacy and Persistence of CAR T Cells", MOLECULAR THERAPY, vol. 5, no. S1, 1 May 2017 (2017-05-01), pages 154 - 154, XP055794713

Citation (examination)

- EP 3336107 A1 20180620 - MILTENYI BIOTEC GMBH [DE] & DATABASE Geneseq [online] 9 August 2018 (2018-08-09), "Human 4-1BB intracellular domain, SEQ:21.", XP093123513, retrieved from EBI accession no. GSP:BFJ88468 Database accession no. BFJ88468
- M. SADELAIN ET AL: "The Basic Principles of Chimeric Antigen Receptor Design", CANCER DISCOVERY, vol. 3, no. 4, 1 April 2013 (2013-04-01), pages 388 - 398, XP055133523, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-12-0548
- LI GONGBO ET AL: "4-1BB enhancement of CAR T function requires NF-[kappa]B and TRAFs", JCI INSIGHT, vol. 3, no. 18, 20 September 2018 (2018-09-20), XP093035954, ISSN: 2379-3708, DOI: 10.1172/jci.insight.121322
- See also references of WO 2019060174A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2019060174 A1 20190328**; AU 2018335266 A1 20200206; CA 3070861 A1 20190328; EP 3684424 A1 20200729; EP 3684424 A4 20210929; JP 2021500859 A 20210114

DOCDB simple family (application)  
**US 2018050417 W 20180911**; AU 2018335266 A 20180911; CA 3070861 A 20180911; EP 18859613 A 20180911; JP 2020516722 A 20180911